
Gujarat's urban roads not designed for so many cars
Feeling exasperated due to heavy congestion during peak hours on city roads? It's not without reason. In 2024, the city (Ahmedabad and Ahmedabad East RTOs) added 560 two-wheelers and 208 four-wheelers daily. This amounts to addition of approximately one new two-wheeler every three minutes and one four-wheeler every seven minutes.
To put the figure in perspective, the 2012 numbers for the same were 499 and 128 respectively, indicating rise of 62.5 per cent in daily registration of four-wheelers and 12.2 per cent for two-wheelers in 12 years.
Surat in comparison recorded a moderate rise with daily two-wheeler registrations increasing from 335 to 384 and four-wheelers from 69 to 84 in 12 years, added the report.
The figures are quoted in the recently-released 'Report of the High-Level Committee on Urban Planning' by the Urban Development & Urban Housing Department of the govt of Gujarat. The report highlighted that Gujarat added 18 lakh new vehicles in 2024 including 12 lakh two-wheelers and 3.5 lakh four-wheelers. In comparison, early 2000s saw the growth of about 41,000 vehicles in a year.
The disproportionate growth of private vehicles puts immense pressure on transport infrastructure, causing congestion, longer travel times, higher emissions and a deteriorating quality of urban life,' the report states.
In contrast, just 4,000 buses are added every year in Gujarat, which underscores the alarming disparity between investment in private and public transport. The disproportionate growth of private vehicles puts immense pressure on transport infrastructure, causing congestion, longer travel times, higher emissions and a deteriorating quality of urban life,' the report states.
The report flags the city's unpreparedness for such a burgeoning population of cars and motorcycles. 'The trend means that in the three or four years, these numbers in Ahmedabad will match registrations in Bangalore (300 cars/day in 2024) and Delhi by 2031 (500 cars/day in 2024). There is no way that our city infrastructure is geared to accommodate such growth, which will result in total gridlock,' the report reads.
Prof Shivanand Swamy, professor emeritus at Cept University and lead author of the section on urban mobility with Prof Shalini Sinha, Keshav Verma (retired IAS officer) and Minal Shetty, told TOI that the roads of Gujarat cities like Ahmedabad are not designed for such high numbers of cars.
"Vehicle composition has been changing over the past few years due to many factors and now we are starting to feel the effect, especially during peak hours. It is a multi-pronged problem with requirements for parking space and more infrastructure such as flyovers. Eventually, they do not provide definite solutions - we must look at an efficient public transport system," he said.
Prof Swamy added that in many European countries, the per person space available is 3-4 metres, compared to which we have about 0.6 metres in several Indian cities.
"Compared to 80-90 buses per 1 lakh people in countries with good public transport, we lag behind by big margin. We may need more than 3,000 buses in the next five or six years or equivalent infrastructure, to serve our growing population and de-congest our roads," he said.
The report highlights issues such an increase in road traffic accidents (RTAs) and deteriorating air quality among other effects of the high vehicle population.
Some recommendations of experts are statutory planning for urban transport, coordinating urban transport intervention through a central body, strengthening transport planning by state or local govt and improved connectivity between regions.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Standard
an hour ago
- Business Standard
G.C Chemie Pharmie: Four Decades of Innovation and Trust in Pharmaceuticals and Nutraceuticals
India PR Distribution Mumbai (Maharashtra) [India], June 6: G.C Chemie Pharmie Pvt. Ltd. (GCCPL), a pioneer in India's pharmaceutical, nutraceutical, functional foods, and biopharmaceutical sectors, proudly celebrates over 44 years of innovation and service excellence. Founded in 1981 by visionary entrepreneur Gautam Shah, GCCPL has evolved into a globally connected and innovation-driven enterprise known for its commitment to trust, transparency, and quality. What began as an API trading and distribution firm has transformed into a diversified pharmaceutical powerhouse. GCCPL's impressive timeline of achievements includes: - 2009/2010: Acquisition of Eagle Chemical Works, establishing its own API manufacturing capabilities - 2009: Release of its first vaccine, marking a significant milestone in biopharmaceuticals - 2010/2011: Launch of its P2P division, introducing affordable medicines to the Indian market -2018: Entry into the sports nutrition space - 2022: Creation of a preventive healthcare division with a focus on gynecology and orthopedics - 2023: Establishment of a dedicated vaccine division to expand immunization solutions Driven by a mission to lead through innovative thinking and technology adoption, GCCPL delivers tailored solutions across pharmaceutical, nutraceutical, and functional food categories. The company continues to differentiate itself through its strong regulatory acumen, cutting-edge R & D, and a global network of manufacturing and distribution partners. "At GCCPL, innovation is not a buzzword--it's the foundation of our growth strategy," said Founder and Chairman Gautam Shah. "We're proud to be one of India's few private companies to bring the pneumococcal vaccine to the domestic market, second only to Pfizer." Recent product highlights include UC-II®, a patented undenatured type II collagen supplement, and Pylopass™, a breakthrough strain-based probiotic--both showcasing GCCPL's commitment to introducing clinically backed, innovative health solutions to India. With a sterling reputation for regulatory compliance, deep market research, and financial integrity--as affirmed by CRISIL's highest rating A2+ GCCPL stands as a trusted partner for businesses and healthcare providers seeking reliable, next-generation healthcare products. About G.C Chemie Pharmie Pvt. Ltd. Founded in 1981, GCCPL is an Indian-based pharmaceutical and nutraceutical company with a global footprint. Known for its reliability, innovation, and commitment to quality, GCCPL offers customized, technology-driven healthcare solutions to meet the evolving needs of today's market. The company maintains a strong presence in vaccines, preventive care, functional foods, and advanced supplements.

Mint
an hour ago
- Mint
Tesla share price climbs 7% after $152 billion selloff even as Elon Musk-Trump truce uncertain; stock down 20% YTD
Tesla shares recouped some losses triggered by a spat between CEO Elon Musk and U.S. President Donald Trump, although a truce appeared uncertain on Friday as a White House official said the president was not keen on talking to his former ally. The stock rose 4% after a steep fall in the previous session that wiped out $152 billion in market value when the world's most powerful man and its richest publicly entered a war of words over the tax and spending bill. Earlier, a Politico report had said Trump and Musk were likely to talk later in the day. Musk had signalled on X he was open to easing tensions with the president, agreeing with calls for a detente from users on the social media platform. Tensions escalated on Thursday after Musk stepped up his criticism of Trump's sweeping tax bill, which proposed largely ending the popular $7,500 EV tax incentive by the end of 2025. In response, Trump suggested cuts to the government's contracts with Musk's companies, including rocket maker SpaceX. Tesla stock is down 29.5% this year after a 14% drop on Thursday. Still, the shares trade at 120 times expected earnings, a lofty multiple compared to other automakers and even tech giants such as Nvidia. The shares have been on a turbulent ride since last July when Musk backed Trump's White House bid. They surged initially as investors bet on less regulatory pressure for robotaxis, but tumbled due to soft sales and brand fallout from Musk's political stance. all Street rebounded on Friday and U.S. Treasury yields jumped as a generally upbeat employment report and a bounce-back in Tesla shares helped put the indexes on track for weekly advances. All three major U.S. stock indexes surged from the starting gate with robust gains, while bitcoin jumped and crude prices touched their highest level since late April. The U.S. economy added 139,000 jobs in May, topping analyst expectations, while the unemployment rate held firm at 4.2%, according to the Labor Department. The report also showed hotter-than-anticipated wage growth, rounding out a report that is unlikely to convince the U.S. Federal Reserve to cut its key policy rate in the near-term. U.S. Treasury yields also rode the wave of the upbeat jobs data. The yield on benchmark U.S. 10-year notes rose 7.5 basis points to 4.47%, from 4.395% late on Thursday. The 30-year bond yield rose 5.1 basis points to 4.9346% from 4.884% late on Thursday. The pan-European STOXX 600 index rose 0.31%, while Europe's broad FTSEurofirst 300 index rose 6.86 points, or 0.31% Emerging market stocks fell 1.29 points, or 0.11%, to 1,181.39. MSCI's broadest index of Asia-Pacific shares outside Japan closed lower by 0.14% to 622.39, while Japan's Nikkei rose 187.12 points, or 0.50%, to 37,741.61. The dollar gained ground against major currencies in the wake of the better-than-expected employment data. The dollar index, which measures the greenback against a basket of currencies including the yen and the euro, rose 0.57% to 99.22, with the euro down 0.48% at $1.1389. Against the Japanese yen, the dollar strengthened 1% to 144.96.
&w=3840&q=100)

Business Standard
an hour ago
- Business Standard
Indian pharma market grows 7.2% in May led by chronic therapies
Indian pharma market grew 7.2% in May with strong performance in chronic therapies such as cardiac and anti-infectives, along with gains from price hikes and new launches Sanket Koul New Delhi The Indian Pharma Market (IPM) grew 7.2 per cent in May this year with almost all major therapies showing positive growth, according to market research firm Pharmarack. Data suggest that big chronic therapies such as cardiac and anti-infectives, which account for nearly 25 per cent of the overall domestic market, recorded value growth of 11.7 per cent and 7.6 per cent, respectively. On the other hand, several smaller supergroups such as urology and antineoplastics, which made up 2 per cent each of the IPM's sales value for the month, also recorded double-digit growth in May at 12.3 per cent and 11.7 per cent, said Sheetal Sapale, vice-president, commercial, Pharmarack. Data suggest that the overall value growth for the IPM in May was driven by price growth and new introductions. The IPM also reported a minuscule 0.4 per cent unit growth during the month, with the chronic segments such as antidiabetics (6.1 per cent) and cardiac (4.8 per cent) performing better than the overall market figure. Experts believe that the antidiabetic segment saw a 6.1 per cent rise in volume in May due to a key drug, empagliflozin, going off-patent, as companies launched several plain and combination medications in the segment. Growth in the moving annual turnover (MAT) for the IPM between June 2024 and May 2025 stood at 8.1 per cent, leading to a total turnover of over Rs 2.29 trillion, while volumes in the domestic market grew by 1.1 per cent. The MAT of leading therapy areas such as cardiac, gastrointestinal and anti-infectives, which constitute around 38 per cent of the pharmaceutical market, showed robust volume growth at 10.4 per cent, 9.5 per cent and 6.5 per cent, respectively. While the top 20 brands in the IPM registered modest monthly value growth in the domestic market during the month, Sun Pharma and Dr Reddy's posted significant monthly value growth at 11.2 per cent each. They were followed by Torrent Pharma and Ipca Laboratories at 10.8 per cent, and Alkem Laboratories at 10.3 per cent monthly value growth. According to Pharmarack data, GlaxoSmithKline's (GSK) antibiotic medication Augmentin and USV's anti-diabetic drug Glycomet GP continued to be the top-selling medicine brands at the MAT level, with sales worth Rs 819 crore and Rs 810 crore, respectively.